news
The first potential treatment for premature ejaculation
Date: 20 November 2009
Source: Medical News Today
Data from a study of PSD502 for the treatment of premature ejaculation, which enrolled and randomised 256 patients from the US, Canada and Poland, are consistent with previous results from Europe and showed that men treated with PSD502 five minutes before intercourse were able to delay ejaculation nearly five times longer than those who used placebo (p<0.001). The mean ejaculatory time in the PSD502 group was 2.6 minutes, compared to 0.8 minutes in the placebo group. Results were presented at the annual meeting of the Sexual Medicine Society of North America in San Diego. Patients and partners in both trials reported statistically significant improvements in sexual satisfaction, and the drug was well tolerated. An estimated one-third of US men ages 18 - 59 are affected by premature ejaculation, making it twice as prevalent as erectile dysfunction. Currently, there are no prescription therapies approved in the US for its treatment. PSD502 is a proprietary formulation of the two drugs lidocaine and prilocaine dispensed by a metered dose aerosol. PSD502 works selectively on non-keratinized skin on the head of the penis.
